The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fate Therapeutics, Inc. (“Fate” or “the Company”) (NASDAQ: FATE) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Fate announced on January 5, 2023, that it had terminated its collaboration and option agreement with Janssen, a Johnson & Johnson subsidiary, related to the development of cell-based cancer immunotherapies. The Company had touted its collaboration agreement as recent as November 2022, but now says all collaboration activities will be wound down in the first quarter of 2023. Based on this news, shares of Fate dropped by 61.45% on the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230106005454/en/